An independent study focusing on somatic regulatory variants in DLBCL confirmed preferential mutation of the PAX5 enhancer in 23% of the germinal center B-cell subtype of DLBCL [261]. This evidence concerns the gene PAX5 and diffuse large B-cell lymphoma.